Answers are grounded in this paper and cite their sources.
The development of selective anticancer agents with minimal toxicity toward normal cells remains a major challenge in cancer therapy. Targeting key regulators of apoptosis and cell-cycle progression, such as Bcl-2 and CDK2, represents a potential strategy for anticancer drug discovery. In this study, a series of newly synthesized anthracene-based heterocyclic derivatives was evaluated through integrated experimental and computational approaches. The quantitative purity of potent compounds 3 and 5 was ensured with HPLC analysis. Cytotoxicity was assessed against human HepG2 hepatocellular carcinoma and WI-38 normal lung fibroblast cells, and IC50 values and selectivity indices (SI) were determined. Compounds 3 and 5 exhibited the highest cytotoxic activity against HepG2 cells, with IC50 values of 7.09 and 9.74 μM, respectively, and favorable SI values of approximately 4–5. Molecular docking was employed to explore the potential interactions of the synthesized compounds with Bcl-2 and CDK2, while Annexin V-FITC/PI staining and flow cytometry were used to investigate apoptosis and cell-cycle effects. Docking analysis indicated favorable predicted interactions of these compounds with Bcl-2 and CDK2 through hydrogen-bonding and hydrophobic contacts. Consistent with their cytotoxic effects, both compounds increased apoptotic cell populations, particularly compound 5, and increased the proportion of cells in the G0/G1 phase relative to untreated control, suggesting disruption of cell-cycle progression. ADME predictions indicated generally favorable drug-like properties for the synthesized compounds, particularly 3 and 5, including high gastrointestinal absorption and acceptable physicochemical characteristics. Overall, the combined biological and computational findings identify compounds 3 and 5 as hit compounds warranting further evaluation in a broader panel of cancer cell lines. The observed cellular effects and docking results provide a preliminary mechanistic rationale for the potential involvement of Bcl-2- and CDK2-associated pathways; however, direct target engagement and inhibition require further biochemical validation. Future studies should include broader cancer-cell panels, target-validation assays, and in vivo evaluation.
No takes yet. Share an insight, caveat, or question.
El‐Helw et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: